30results about How to "Increase ovulation rate" patented technology

The invention discloses a slow-release oxytocic agent for artificially inducing grouper gonad development and maturation, ovulation and ejaculation. 10%, 75-95% cholesterol, 1-19% cellulose; 1-3% vegetable oil is added to the formula components, mixed evenly, and cylindrical pills are made with a special mold. The invention is used to bury the grouper in the body to induce the maturation of the gonads to achieve ovulation and sperm discharge, so as to meet the needs of the grouper artificial seedling industrialization and large-scale breeding for seedlings.

The invention discloses a method for inducing Stichopus Japonicus Selenka to lay eggs in vivo, which is characterized by simple operation, short time, synchronous egg laying, large discharge quantity and good quality of eggs, and capability of greatly improving induction rate, fertility rate and hatching rate; the method is implemented as the following steps: dissolving NGLWY acid amides in ultrapure water to formulate 1 mumol / L mother liquor, then dissolving the mother liquor in 0.5mol / L KCl sea water solution to prepare 1nmol / L inducer; selecting gonad mature parent Stichopus Japonicus Selenka with the weight being at least 200g; injecting the inducer with the ratio of volume and the weight of parent Stichopus Japonicus Selenka being 0.1% ml / g but less than 0.3ml into coelom from the back of the Stichopus Japonicus Selenka to perform in vivo induction; and collecting the eggs.

The invention relates to a Chinese medicinal composition for a kidney-yang deficiency and phlegm-retention type polycystic ovary syndrome. The Chinese medicinal composition comprises the following medicinal materials of epimedium, caladium, semen psoraleae, sliced deerhorn, sea horse, tortoise plastron and the like, does not contain rhubarb and Chinese angelica. The Chinese medicinal composition can reduce the level of androgens and androgen receptors of polycystic ovanian syndrome (PCOS) patients, improve the level of sex hormone binding globulin, reduce the level of free testosterone, improve the level of in-vivo estrogens, improve the growth and development of follicles and improve the ovulation rate and pregnancy rate of patients.

The invention provides a method for increasing the ovulation rate of sinonovacula constricta (Lamarck) parent oysters and guaranteeing ovulation synchronism. An inonovacula constricta (Lamarck) parent oyster ovulation device employed comprises a rectangular bottom frame, supporting rods, a shielding film and a light-dimming window, wherein small holes are drilled in the four corners of the bottom frame, the four supporting rods are inserted into the small holes to form a cuboid-shaped frame, the shading film as high as the supporting rods is put to surround the cuboid-shaped frame, and the light-dimming window is paved at the top of the cuboid-shaped frame; the bottom of the bottom frame is covered with a nylon net; an air inlet pipe is laid in the longitudinal direction of the bottom frame; three air stones are connected under the air inlet pipe. When the inonovacula constricta (Lamarck) parent oyster ovulation device is applied for ovulation, the light intensity in the light-dimming window is controlled at 200Lx, and therefore, the ovulation synchronism of the inonovacula constricta (Lamarck) is guaranteed, and meanwhile, the ovulation rate of the sinonovacula constricta (Lamarck) parent oysters is greatly increased and the shortcomings of the prior art are solved; meanwhile, the whole device is very convenient to assemble and disassemble, easy to clean and low in cost, and cannot be corroded by seawater; the method can be popularized in actual production very easily.

The invention relates to a medicinal composition for a high-androgen polycystic ovary syndrome. The medicinal composition comprises a Chinese medicinal composition and a chemical medicament, wherein the Chinese medicinal composition comprises the following medicinal materials: epimedium, caladium, fructus psoraleae, sliced deerhorn, sea horse, tortoise plastron and the like, and does not contain rhubarb and Chinese angelica. The medicinal composition can reduce the level of androgen and androgen receptors of polycystic ovary syndrome (PCOS) patients, improve the level of sex hormone binding globulin, reduce the level of free testosterone, improve the level of in-vivo estrogen further, improve the growth and development of follicles, and improve the ovulation rate and pregnancy rate of thepatients.

The invention provides a pharmaceutical composition for treating polycystic ovary syndrome (PCOS). The pharmaceutical composition consists of a traditional Chinese medicine composition and chemical drugs, wherein the traditional Chinese medicine composition comprises the medicinal materials such as anemarrhena, fritillary bulb, tortoise plastron, fleece-flower root, lilyturf root, hippocampus andthe like; and the chemical drugs comprise one or more compound molecules of dexamethasone, spirolactone, ethinyloestradiol, estradiol valerate, conjugated estrogen and pharmaceutically acceptable salt. The pharmaceutical composition has the advantages of reducing the level of androgens and androgen receptors of patients suffering from PCOS, improving the level of sex hormone-binding globulin (SHBG), lowering the level of free testosterone (F-TESTO), further raising the level of in-vivo estrogens, improving growth and development of follicles and increasing ovulation rate and pregnancy rate ofthe patients.

The present invention firstly provides a method for promoting kelp female gametophytes to discharge eggs. First, the kelp germplasm filaments are recovered in seawater, then the kelp germplasm is crushed, and the crushed liquid is filtered to obtain cells with a length of 3-6. The obtained filamentous body fragments; then the obtained filamentous body fragments were subjected to aerated suspension culture under the conditions of light intensity 6000±300lx, light cycle: L:D=12h:12h, and temperature 15±1°C to collect eggs; and then The collected eggs are cultured to obtain laminar sporozoites, and the laminar sporozoites are cultured, and the young sporophytes of the two rows of cells are cultured in flowing water. The method of the present invention enables the kelp female germplasm to ovulate in 11-13 days, shortening the ovulation time; and the ovulation rate is high and well synchronized, and the ovulation rate can reach 65-70% within 2 days; the egg development rate can reach 70-80% %. The established young sporophyte culture method can reduce the deformity rate of the young sporophyte to 50%-60%.

The invention provides a method for improving gonad development of tegillarca granosa. The gonad development of the tegillarca granosa is improved by feeding thraustochytrium roseum during cultivation of parent scallops of the tegillarca granosa. The gonad development of the tegillarca granosa is greatly fastened by feeding the thraustochytrium roseum in cultivation of the parent scallops of the tegillarca granosa, egg-laying time of the parent scallops of the tegillarca granosa is effectively controlled, management of breeding production of seedlings of the tegillarca granosa is greatly facilitated, and ovulation rate of the parent scallops of the tegillarca granosa is greatly increased.

The invention provides a traditional Chinese medicine composition for treating kidney-yin deficiency and phlegm-blood stasis polycystic ovary syndrome (PCOS). The traditional Chinese medicine composition comprises the medicinal materials such as anemarrhena, fritillary bulb, tortoise plastron, radix polygoni multiflori preparata, lilyturf root, hippocampus and the like. The medicinal materials are cooperative with each other so as to realize the efficacies of nourishing kidney and clearing away heat and reducing phlegm and removing blood stasis. The traditional Chinese medicine composition has the advantages of reducing the level of androgens and androgen receptors of patients suffering from PCOS, improving the level of sex hormone-binding globulin (SHBG), lowering the level of free testosterone (F-TESTO), further raising the level of in-vivo estrogens, improving growth and development of follicles and increasing ovulation rate and pregnancy rate of the patients.

The invention discloses a pharmaceutical composition for treating obese polycystic ovary syndrome. The raw materials are composed of 4-8 parts of ginger pinellia, 25-35 parts of fairy spleen, 8-12 parts of atractylodes rhizome, 16-24 parts of poria cocos, 10-14 parts of tangerine peel, 25-35 parts of Dipsacus, 8-12 parts of Cyperus cyperi, 16-24 parts of Salvia miltiorrhiza, 8-12 parts of Achyranthes knuckles, 8-12 parts of plantain seed, 4-8 parts of cinnamon, 4 parts of roasted licorice ‑8 servings. The medicinal materials selected for the pharmaceutical composition of the present invention are compatible, the prescriptions are refined, and the functions complement each other. The purpose is to promote dampness and eliminate phlegm, and it integrates expectorant, warming kidney, promoting qi, invigorating the spleen, promoting blood circulation, and tonifying. Significant; in terms of medicinal properties, they are compatible with each other, with less toxic and side effects.